News
Zacks Investment Research on MSN1d
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...
Pharmaceutical Technology on MSN4d
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumblesAdditional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback